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Introduction: Epithelioid hemangioendothelioma is a rare vascular tumor that has an epithelioid and histiocytoid
appearance, originates from vascular endothelial or pre-endothelial cells and comprises less than 1% of all vascular
tumors. It was described for the first time in 1975 as pulmonary epithelioid hemangioendothelioma, because initially
it was believed to be an aggressive form of bronchoalveolar cell carcinoma with a remarkable propensity to
invade adjacent blood vessels and small airways. Only a few cases have been reported in the literature to date.
Tumor cells expressing Fli-1 and CD31 have been identified as relatively specific endothelial markers. Epithelioid
hemangioendothelioma may affect multiple organs and may vary considerably in its clinical and radiological
presentation. More than 50% to 76% of pulmonary epithelioid hemangioendothelioma patients are asymptomatic.
They are usually incidentally diagnosed on the basis of abnormal chest radiography during routine physical examinations.
Hematologic and gastrointestinal disorders and weakness or numbness may also be observed, in addition to respiratory
symptoms, in cases of disseminated pulmonary epithelioid hemangioendothelioma. Pain and swelling, pathological
fractures, spine compression or paresthesia, loss of muscular strength and paraplegia may be present when bone
metastases occur. Because of the rarity of this disease, there is no standard for treatment.
Case presentation: A 46-year-old Caucasian woman presented to our institution in November 2009 with metastases
of pulmonary epithelioid hemangioendothelioma from the L3 and L4 vertebrae. A course of radiotherapy at a dosage
of 3,000cGy delivered in individual doses of 200cGy/day for 5 days/wk to the L3 and L4 vertebrae led to the
disappearance of the patient’s lumbar pain without any detectable side effects. Percussion of the patient’s vertebral
spine was negative, and no radiological progression of bone disease was found at her 1-year follow-up examination.
Conclusion: Since epithelioid hemangioendothelioma was first correctly defined, several research groups have
reported their experiences with epithelioid hemangioendothelioma irradiation. Further studies are needed to establish
a standard radiation dose to be used for such a complex and extremely rare disease. In our present case, a
radiotherapy dosage of 3,000cGy delivered in individual doses 200cGy/day for 5 days/wk allowed us to reach our goals:
local pain control with good tolerance and better quality of life by the 1-year follow-up examination.
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Representing less than 1% of all vascular tumors, epitheli-
oid hemangioendothelioma (EHE) is a rare vascular tumor
with an epithelioid and histiocytoid appearance that origi-
nates from vascular endothelial or pre-endothelial cells.
It was described for the first time in 1975 by Dail et al.
as pulmonary epithelioid hemangioendothelioma (PEH).
Initially, it was believed to be an aggressive form of bron-
choalveolar cell carcinoma with a remarkable propensity
to invade adjacent blood vessels and small airways; hence
the name intra-vascular bronchioloalveolar tumor [1].
The term epithelioid hemangioendothelioma was intro-
duced in 1982 by Weiss and Enzinger in describing a vas-
cular tumor of bone and soft tissue with intermediate
malignancy and features between hemangioma and angio-
sarcoma [2]. Weldon-Linne et al., by using electron mi-
croscopy, confirmed previous findings about these tumor
cells that they derive from a lineage capable of differenti-
ation along endothelial lines. By immunohistochemistry,
they revealed diffuse cytoplasmic staining of the malignant
cells with a factor VIII–related antigen, which clarified the
endothelial lineage of these tumor cells [3].
The World Health Organization 2002 classification [4]
describes such tumors as lesions that fall into the category
of locally aggressive tumors with metastatic potential.
Therefore, some authors began to believe the hypothesis
that EHE does not represent a distinct entity, but rather is
an intermediate state of endothelial dedifferentiation with
a highly variable and unpredictable prognosis [5].
Herein we present the case of a patient with extensive
dissemination and serious bone damage due to PEH who
benefited from radiation therapy (RT) for pain and control
of local bone recurrence.
Case presentation
A 46-year-old Caucasian woman presented to our institu-
tion in November 2009 with L3 and L4 vertebrae metasta-
ses of PEH. Previous thoracopulmonary investigations had
revealed multiple disseminated pleuropulmonary nodules
followed by pulmonary wedge resection, confirming the
typical clinical PEH immunoreactivity for CD31, factor
VIII, Fli-1 and vimentin. She had also undergone lumbar
computed tomography (CT), which showed structural
changes in the third and fourth lumbar vertebrae (L3-L4)
combined with a partially collapsed L4 and L3-L4 disc
protrusion. Her abdominal CT scan had shown a small,
common iliac vein thrombosis and a small caval throm-
bosis immediately above the iliac venous confluence. All
of these findings together led to initiation of therapy with
polyethylene glycol and interferon α at a dosage of 1μg to
2μg once every 7 days. A CT scan performed 4 months
after initiation of treatment revealed stable lung disease
but new hypodense splenic lesions. A lumbar spine
magnetic resonance imaging scan showed exacerbationof bone disease with worsening L3 and L4 collapse and
further L4-L5 disc protrusion. Therefore, she under-
went kyphoplasty. The bone biopsy performed during
the operation confirmed the diagnosis of L4 vertebral
body EHE.
When the patient presented to our institution, she
complained of back pain that did not go away after taking
common anti-inflammatory drugs and treatment with
lumbar vertebrae acupressure. The pain was absent in
other areas. On the basis of the scarce available literature
on patients with this presentation, we delivered symptom-
atic RT into the L3-L5 vertebral tract using a 3,000cGy
total target dose in 200cGy daily fractions 5 days/wk. At
the end of the treatment, the patient’s lumbar pain had
disappeared and she experienced no detectable side ef-
fects. In 2010, we observed negative percussion of the ver-
tebral spine and no radiological progression of bone
disease. The patient underwent ifosfamide and epirubicin
chemotherapy and surgical removal of EHE spleen lesions
soon after her follow-up examination at our institution.
She died in October 2010 as a result of PEH progression.
Discussion
After Dail et al. first identified PEH in 1975 [1], in 1982
Weiss and Enzinger used the term epithelioid hemangioen-
dothelioma to describe a vascular bone and soft-tissue
tumor with intermediate malignancy between hemangioma
and angiosarcoma [2]. Weldon-Linne et al. discovered a
factor VIII–related antigen in malignant cells, confirming
their endothelial origin [3]. The median age of onset is 36
years (range, 20 to 60 years) [6]. The most common pre-
sentations are liver alone (21%), liver plus lung (18%), lung
alone (12%) and bone alone (14%) [7]. Approximately 50%
to 76% of patients are asymptomatic. Some present with
chest pain, pleuritic pain, cough, dyspnea, malaise [8],
hemoptysis and anemia. Bone metastases cause pain
and swelling in the affected area, pathological fractures
[9], spine compression if the lesions arise in vertebrae,
which result in paresthesia, loss of muscular strength
and paraplegia [10]. Hematologic and gastrointestinal
disease, as well as weakness or numbness, may also
occur because of EHE dissemination [7]. Radiologically,
PEH consists of multiple bilateral perivascular nodular
opacities with a diameter ≤1cm [10], and sometimes
present with lymph node metastases, pleural thickening
or ground-glass opacities. Bone metastases appear as
osteolytic lesions with homogeneous contrast enhance-
ment, cortical disruption and soft-tissue swelling [9].
Histologically, the tumor has a micropolypoid growth,
and tumor cells with cytoplasmic vacuoles occasionally
contain erythrocytes [11] expressing Fli-1 and CD31 [12],
which are relatively specific endothelial markers. The
overall survival rate of EHE patients is better when the
disease is localized (90% at 1 year and 73% at 5 years)
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and 24% and 5 years) [7].
Because of the rarity of this disease, there is no stand-
ard for treatment. Curative resection achieves good out-
comes. Usually, adjuvant RT is used to control residual
disease for patients with localized EHE. Chemotherapy
(interferon 2α or carboplatin plus etoposide) is the pre-
ferred therapy for patients with widespread disease, but
the benefits of these drugs are unclear [1,6,13].
Because of the radiobiological characteristics of PEH
(slow growth), RT is ineffective. Good local control has
been reported in a patient with exclusive EHE bone pres-
entation treated by combining RT with bone surgery [14].
From the time EHE was correctly defined, several research
groups have studied irradiation for EHE. A protocol of
4,000cGy for 4 weeks [13], followed by a 3,000cGy course
of RT to the spine after surgical removal of EHE of the
vertebrae [15] has been described. In the study reported
by Aquilina et al., one patient survived for 11 years, but
the other patients experienced worsening conditions due
to multiple hepatic and abdominal metastases. Authors
of another report described adjuvant RT delivered at
dose of 6,400cGy to treat axillary EHE, which resulted
in the absence of lymph node metastases but widespread
pleuropulmonary metastasis [6]. Local irradiation after
bone EHE resection at 6,000cGy in 23 fractions for 43
days showed good tolerance, without regional or distant
metastases or local recurrence at 6-, 12- and 24-month
follow-up examinations [10]. A recently reported protocol
of 33 radiation fractions totaling 5,940cGy was applied to
treat residual mastoid EHE. The authors found that im-
aging performed 8 years after surgery and RT revealed
neither recurrence nor any change in the patient’s clinical
status [16].Conclusion
Further studies are needed to establish the standard radi-
ation dose to be used for locoregional control of this com-
plex and extremely rare disease. In our present case, a RT
dosage of 3,000cGy delivered at 200cGy/day 5 days/wk
allowed us to reach our goals: local pain control with good
tolerance and better quality of life at the 1-year follow-up
examination.Consent
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next of kin for publication of this case report and any ac-
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